ICYMI: ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain
The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.
Read Article
Who/When to Treat Clinically Suspect Arthralgia
Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA)
https://t.co/78b6COM2fZ https://t.co/ucRoPER8N1
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by https://t.co/Ae8pCXz8Wh
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs
A retrospective US administrative claims cohort study of RA patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) found a statistically significantly higher risk of incident cancer in patients receiving rituximab, abatacept, or JAKis (
Read Article
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs.
@RheumNow
#EULAR2025 #OP0033 https://t.co/nEiTWQEqsP
Dr. John Cush @RheumNow( View Tweet )
If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix?
Leiden post-hoc trial: these patients don’t do worse than those who never get off drug.
Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/bwXgrB875k
Dr. John Cush @RheumNow( View Tweet )
ICYMI: AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.
Read Article
How to patients with rheumatic diseases consume online health information?
78% used internet for health information
50% use it atleast a month
66% found online information superior
41% used social media!
80% using it to find treatment optio ns!
@rheumnow #EULAR2025 https://t.co/ZcjwPaqsjT
Dr. John Cush @RheumNow( View Tweet )
#EULAR2025 in numbers
💫5125 abstracts submitted from 95 countries
💫177 scientific sessions
💫350 speakers from 45 nations
💫Balanced gender split of speakers & chairpersons
💫Fresh sessions format
💫Integration of European Workshop for Rheum Research https://t.co/7WoknFuVLL
Dr. John Cush @RheumNow( View Tweet )
Rituximab - Super Responders Exist in SLE
Dr. Yuz Yusof reports on abstract POS0325 presented at the 2025 EULAR meeting in Barcelona.
https://t.co/LkYzMtsErn https://t.co/awRhQmbhoT
Dr. John Cush @RheumNow( View Tweet )
ICYMI: TNF Inhibitor Drug-Induced Lupus
A study from the FDA's adverse event reporting system (FAERS or Medwatch) database identified cases of drug induced systemic lupus erythematosus (SLE) in patients receiving tumor necrosis factor-α (TNF-α) inhibitors - a paradoxical reaction to common antiinflammatory biologic agents.
Read Article
ICYMI: Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more comorbidity, smoking and corticosteroid use.
Read Article
ARD's Impact Factor
The 2024 Impact Factor for ARD is 20.6 – an increase from 20.3 in 2023. This retains the journal’s position as second of 58 titles in the rheumatology category and confirms its status as the top-ranking journal for the publication of original research in both https://t.co/dtMTejkhcc
Dr. John Cush @RheumNow( View Tweet )
Pregnancy in SLE: Risks Extend Beyond Clinical Concerns
Pregnancy in patients with systemic lupus erythematosus (SLE) continues to carry significantly elevated risks, with maternal mortality rates nearly five times higher than in the general population.
https://t.co/3G7Eftt0Kg https://t.co/X3SUl6FTHO
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Axial Involvement in Psoriatic Arthritis
Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.
Read Article
ICYMI: Proinflammatory Diet Increases Gout Risk
MedPage Today
Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated. Data from the two iterations of the Nurses' Health Study, in which more than 170,000 women were followed for more than two decades, indicated that diets scoring high on the Empirical Dietary
Read Article
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have
Read Article
All Rheumatoid Arthritis is Not the Same
Dr. Jonathan Kay reviews abstracts OP0323 and OP0328 from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/rbK3Y1NHVI https://t.co/eYPdbx87kt
Links:
Dr. John Cush @RheumNow( View Tweet )
Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life
Dr. Jiha Lee reports on abstract POS0402 - THE ROLE OF AGEING IN THE RELATIONSHIP BETWEEN CHRONIC MUSCULOSKELETAL PAIN AND HEALTH-RELATED QUALITY OF LIFE: THE MAASTRICHT STUDY - presented at the 2025 EULAR https://t.co/AiP57hXIRB
Dr. John Cush @RheumNow( View Tweet )
Remission in Axial Spondyloarthritis Unrelated to Gut Inflammation
Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal https://t.co/Sa10k6neRP
Dr. John Cush @RheumNow( View Tweet )
Simple Measures are Effective in Knee Osteoarthritis
Knee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of https://t.co/4VQpKQJwXu
Dr. John Cush @RheumNow( View Tweet )
PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read Article
There's an App for That (and it works): the AXIA RCT
Dr. Aurelie Najm reports on abstract LB0002 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/IRZ1L7BqLW https://t.co/Av2vVheShE
Links:
Dr. John Cush @RheumNow( View Tweet )
What we need in very early arthritis
It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all https://t.co/v8T3JQwuhM
Dr. John Cush @RheumNow( View Tweet )
Korean Health claims data study of 35,133 newly Dx, seropositive #RA pts (2011 to 2020) & 1,386 (3.9%) were Dx w/ new-onset stroke (CVA). Signif. lower risk of CVA w/ SSZ (aOR: 0.79) or HCQ (aOR: 0.83), but Increased risk w/ glucocorticoids (aOR: 1.71) & tocilizumab (aOR: 3.47) https://t.co/rPaj6cH74K
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
